by Ken Terry | Oct 24, 2018 | Blog
One of the trickiest jobs of a PR professional consists of guiding corporate executives to the proper mix of marketing and thought leadership in various types of writing.
The easy part, relatively speaking, is persuading them that if they insist on promoting their product directly in a bylined article, it won’t be published. In case they have any doubts, you can just suggest that they take a look at the publication online and see if any of its articles are marketing-oriented.
On the other hand, by its nature a case study or a press release is strictly promotional. Readers expect that the story will focus on a product or a business deal and that it will be structured to make the company and the product look as good as possible.
But the boundaries are much more porous when it comes to white papers, sometimes known as position papers. Over the years, I’ve worked for clients who have had many different ideas about what such papers should be.
Ultimately, of course, they all wanted to sell their products. But only some executives grasp the concept of a truly effective white paper: It should draw in readers with a point of view about an industry trend and promote the company’s product indirectly by showing the need for it.
The rest want me to blatantly list the advantages of their product somewhere in the paper. To them, it’s just another form of advertising.
I don’t know whether a rigorous study has ever been done to measure the readership of these two kinds of papers, controlling for length and the demand for information on the topic. But I’d venture to guess that industry stakeholders would be more interested in a paper that gave them information they could use than in another piece of marketing collateral.
Interestingly, big companies are no more likely than small ones to embrace the concept of true thought leadership pieces. Because they’re big, they may commission longer papers that have space to discuss industry trends or government regulations at greater length. But in the end, they still usually want their product promoted, with hardly a fig leaf to cover it.
It was actually a small, rapidly growing firm that gave me the widest rein to show its thought leadership and vision. Over a period of several years, I wrote a dozen or more white papers that helped build the company’s reputation for expertise in population health management.
I always mentioned the need for health IT solutions that could help healthcare organizations manage population health. But for the most part, the papers focused on topics that people needed to know about, ranging from accountable care organizations (ACOs) and patient-centered medical homes to care coordination, patient engagement and post-discharge care. Eventually, the company pulled together my essays into a book that it used effectively as a sales tool.
White papers and byliners are not the only vehicles for thought leadership. Occasionally, if a company CEO is a recognized expert in a particular area, you might be able to get a major publication such as the Wall Street Journal or the Washington Post to publish a thought leadership piece by that person.
The easiest way to do this, by the way, is to pitch a letter to the editor. But it has to be on a hot topic, and you have to get it in very quickly.
One way to show a company executive the difference between marketing and thought leadership is to ask him or her where they see a bylined article or position paper being published. If they say they’d like to reach a broad universe, you advise them to think about thought leadership. If they insist on a marketing message, you tell them that it’s probably only going to be posted on their website or printed up for use by their salespeople.
A sophisticated PR professional or marketer knows that organizations need the right mix of these two kinds of communications to be successful. But thought leadership should be part of the package so that companies can impress potential clients with their deep knowledge and brilliant insights.
After reading a white paper or a bylined piece of this type, the potential buyer will probably not go running to your client. But when the organization’s salesperson comes calling, they’re likely to remember something about the company that caught their attention.
Like medicine and angling, PR is as much an art as a science. What it takes to help organizations succeed depends on how many tools you have in your toolkit, and how many different approaches you try. Eventually, if your executives trust you, they will land a fish or two.
by Lisa Chernikoff | Apr 11, 2018 | Blog
We’ve all heard of analysis paralysis the state of over-analyzing or over-thinking a situation so much that a decision is never made and the outcome is impacted. Recently I’ve been witnessing a curious yet similar phenomenon at healthcare IT companies across the country and the analysis paralysis is all about “strategy.” As in overall corporate strategy and direction.
In short, these companies are all about strategic planning, but in the end they seem to come out of it having virtually no strategic plans. They’re all about all-day strategy meetings which result in no strategy but rather more questions that prompt more all-day meetings and shockingly, yet still no strategy.
From the outside looking in, this cycle is an endless hamster wheel that leaves team members feeling tired rather than energized, frustrated rather than empowered, and most troublingly, so terrified that their actions won’t follow the still-to-be-approved (or never-to-be-approved) strategy that they simply don’t act. This inaction can be minor or major as it builds up over time but it’s always detrimental.
Back to basics to get results
Their “strategic focus,” while well-intentioned, sets companies on the wrong path in the short and long-term, especially in regards to PR which should have a constant, ongoing cadence to create momentum and maximize results.
While company strategies can be complicated and have a profound impact on PR efforts, many aspects of PR strategy are quite uncomplicated. In fact, there are core tenets which are quite basic and fundamental to any sound PR plan. There are the pillars that cannot be disputed so they need not be delayed regardless of executive indecision.
Whether your strategy is set or you’re one of many stuck on the endless hamster wheel, these four actions are key to success. They are mission-critical, and safely fit into any PR strategy for 2018 and beyond:
1. Write and distribute press releases
It sounds like a no-brainer but for many companies it’s not because they live in fear of being “off brand” or “misaligned.” They live in fear of putting out too many press releases yet not enough press releases. Those fears are unwarranted though since your company is doing good work. Why shouldn’t it be shared? Did you develop a new product? Let’s write a release. Did you sign a new customer? Let’s write a release. Is your CEO speaking at an industry event? Let’s write a release.
Writing a press release is one of the simplest ways to communicate what’s happening and why it matters. Distributing those press releases positions your company as a key player and thought leader in the ongoing industry dialogue. It’s not complicated. It doesn’t need to be debated and as long as you’re not regularly putting out more than 2-4 press releases per month, you’re not overdoing it. So, just do it.
2. Highlight your customer’s success stories
Once again, it sounds like a no-brainer. You have customers. They like your products. They like your team. They have achieved impressive results that they’re willing to share. Let them be your advocates. Capture their stories in writing. Put them in front of reporters who are eager to hear from both executives and end-users at provider organizations. It’s as simple as that. Just like with press releases, these customer success stories illustrate that your company is doing good work and that’s what makes more customers want to work with you, which of course is one of the biggest end goals of any strategy. It’s not complicated. It doesn’t need to be debated. As long as your customers are singing your praises, hand over the microphone and let them sing.
3. Emphasize your expertise
In addition to highlighting your clients, highlight your company’s thought leaders. After all, they are also doing good work (you may see a pattern here). They have knowledge to share. They have ideas to contribute. They are the faces of your company and you need some faces even if you don’t have a final strategy. This action can mean authoring bylined articles or blogs on their behalf or pitching them as experts for media interviews. By positioning your executives and SMEs as thought leaders and joining the industry conversation, you’re helping to make your company a go-to source for future media opportunities. It’s not complicated. It doesn’t need to be debated and it would really be a shame for their knowledge to go to waste.
4. Educate your sales team about PR efforts
Regardless of strategy indecision, your sales team needs to close deals. There is nothing off-strategy about building your business. Media placements from your PR efforts are one of the most powerful but underutilized tools in your sales team toolkits. Obviously, sales prospects are not interested in the same information as the media. In fact, they may be turned off by being sent a press release about a new client that just signed on. However, they may be very interested in press coverage from well-regarded industry publications that profile your company news, thought leadership, and customer success stories. That is not only informative but also adds credibility and implies that you want to keep them in the know.
Similarly, if one of your client case studies is featured in a third-party publication, that’s a prime opportunity to reach out, share the article and offer a reference call with the client quoted. It’s not complicated. It doesn’t need to be debated and if you’re earning media placements it is certainly a shame not to use them to their fullest potential.
It’s time to get off the hamster wheel and get on with the real work that makes a difference.
by admin | May 30, 2017 | News
Scottsdale, Ariz. May 30, 2017 Amendola Communications, an award-winning healthcare marketing and public relations agency, announced today that Bridge Therapeutics, Inc., has selected Amendola as its agency of record. Bridge Therapeutics, an innovative development-stage specialty pharmaceutical company, will be pursuing FDA and European Medicines Agency (EMA) approval of a patented (U.S. Patent #8410092) novel drug combination for the treatment of chronic pain in opioid-experienced patients.
Bridge selected Amendola after a rigorous agency review process. Amendola will provide a broad range of public relations and thought leadership services that promote Bridge Therapeutics as a pioneer and innovator in improving the lives of patients living with chronic pain through safer, more effective, and less addictive pain management.
Bridge Therapeutics investigational drug compound BT-205 is a unique combination of two synergistic chronic pain drugs the partial-agonist opioid buprenorphine and the NSAID meloxicam delivered in a state-of-the-art sublingual formulation. BT-205 is being developed to replace dangerous, full-agonist opioid-based drugs with a safer and more effective medication.
“We are excited that Amendola Communications will help us to bring our message about safer approaches to those struggling with chronic pain and addiction to the market,” said Alton Kelley, director of business development for Bridge Therapeutics. “Chronic pain affects more 100 million Americans today, which the Institutes of Medicine report is more than diabetes, heart disease and cancer combined. As we go through the FDA and EMA approval and commercialization process, we look forward to partnering with Amendola to help us educate the market about the benefits of replacing dangerous opioid-based drugs with a safer and more effective therapy for those struggling with chronic pain and addiction.”
BT-205 has the potential to be a new treatment option for healthcare providers around the world, and to offer patients an alternative chronic pain therapy. When dosed as a combination drug, buprenorphine and meloxicam have stronger pain relief effects, which allows the use of low dosage strengths of both and reduces the potential for negative side-effects.
Amendola Communications will provide targeted strategic public relations services, including media research, media relations, and the generation of top-tier awards and speaking opportunities. The agency will also be responsible for delivering a range of content demonstrating the thought leadership and expertise of Bridge Therapeutics key opinion leaders (KOLs), including bylined articles, poster presentations, press releases and other materials.
“Bridge Therapeutics offers an exciting and innovative approach to addressing the opioid addiction crisis facing our nation today,” said Jodi Amendola, CEO of Amendola Communications. “Addictive chronic pain drugs today kill more Americans than road crashes, and yet the massive chronic pain market in the United States still lacks a non-addictive pain medication. We look forward to promoting Bridge Therapeutics and its key opinion leaders as the company continues to go through its regulatory approval and commercialization process.”
About Amendola Communications
Amendola Communications is an award-winning national public relations, marketing communications, social media and content marketing firm. Named one of the best information technology (IT) PR firms in the nation four times by PRSourceCode, Amendola represents some of the best-known brands and groundbreaking startups in the healthcare and HIT industries. Amendola’s seasoned team of PR and marketing pros delivers strategic guidance and effective solutions to help organizations boost their reputation and drive market share. For more information about the PR industry’s “A Team,” visit www.acmarketingpr.com, and follow Amendola on Twitter and LinkedIn.
About Bridge Therapeutics
Bridge Therapeutics, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs the partial-agonist opioid buprenorphine and the NSAID meloxicam delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics’ goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory. The company is focused on improving the lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and less addictive. For more information, visit www.bridgetherapeutics.com.
Media Contact: Tara Stultz | 440.225.9595 | tstultz@acmarketingpr.com
